ROSEN, TRUSTED INVESTOR COUNSEL, Encourages CarMax, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – KMX

New York, New York–(Newsfile Corp. – November 27, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of CarMax, Inc. (NYSE: KMX) between June 20, 2025 and November 5, 2025, both dates inclusive (the “Class Period”) of the important January 2, 2026 lead plaintiff deadline in the securities […]

SafeNew AI Launches Humanizer Engine to Restore Natural Writing in an AI-Driven World

LOS ANGELES, Nov. 27, 2025 (GLOBE NEWSWIRE) — SafeNew AI announced the launch of its Humanizer Engine, a tool designed to convert AI-generated text into natural, human-sounding writing while maintaining meaning and intent. With AI writing tools becoming increasingly common, AI-generated text can often feel robotic, overly structured, and repetitive. Users–including students, educators, and writers–spend

SafeNew AI Launches Humanizer Engine to Restore Natural Writing in an AI-Driven World

SafeNew AI Launches Humanizer Engine to Restore Natural Writing in an AI-Driven World A new linguistic engine transforms AI-generated text into natural, human-sounding writing while preserving accuracy and intent. GlobeNewswire November 28, 2025 LOS ANGELES, Nov. 27, 2025 (GLOBE NEWSWIRE) — SafeNew AI announced the launch of its Humanizer Engine, a tool designed to convert

Trimera Metals Announces Effective Date of Name and Symbol Change

Vancouver, British Columbia–(Newsfile Corp. – November 27, 2025) – Trimera Metals Corp. (CSE: TRM) (OTCQB: TRMMF) (FSE: O2S) (“Trimera” or the “Company“) is pleased to announce that it has changed its name from “Trimera Metals Corp.” to “United Critical Minerals Corp.” and its Canadian Securities Exchange (“CSE“) ticker symbol from “TRM” to “UCM” (together, the

Faraday Future Hosts FX Super One Delivery Ceremony for Soccer Legend Andres Iniesta in Dubai; Middle East Operations Enter Product Delivery and Revenue Phase

(NASDAQ:FFAI), Marks the solid execution of FF and FX's Global Automotive Bridge Strategy in the Middle East, signaling a new phase in the Company's Middle East Three-Pole strategy and lays a core foundation for future sales. FF and FX will expand Co-Creation initiatives with FX Super One's first global owner and Developer Co-Creation Officer Andres

Faraday Future Hosts FX Super One Delivery Ceremony for Soccer Legend Andres Iniesta in Dubai; Middle East Operations Enter Product Delivery and Revenue Phase

Faraday Future Hosts FX Super One Delivery Ceremony for Soccer Legend Andres Iniesta in Dubai; Middle East Operations Enter Product Delivery and Revenue Phase GlobeNewswire November 28, 2025 Marks the solid execution of FF and FX's Global Automotive Bridge Strategy in the Middle East, signaling a new phase in the Company's Middle East Three-Pole strategy

Cross over to Adventure: Agoda’s Guide to Must-Visit Bridges in Asia

Digital travel platform Agoda has released a list of must-visit bridges across Asia, showcasing the architectural beauty and cultural significance of these unique destinations. Bridges have long been more than just functional structures; they are symbols of connection, history, and artistry. For travelers, visiting these bridges offers a unique glimpse into the heart of a

Media Invitation: Golden Singa Awards 2025 – Press Conferences, Red Carpet & Ceremony

The inaugural Golden Singa Awards 2025, organised by NoonTalk Media Limited, will take place on 1 December 2025 at The Capitol Theatre in Singapore. Bringing together renowned artistes, filmmakers, and industry leaders from across the region, the Awards will serve as a vibrant celebration of creativity, talent, and cultural exchange. Members of the media are

InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis

(HKSE:9969), BEIJING, Nov. 27, 2025 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the global Phase II clinical trial of its novel TYK2 inhibitor, Soficitinib (ICP-332), for the treatment of patients

InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis

InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis GlobeNewswire November 28, 2025 BEIJING, Nov. 27, 2025 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the

Scroll to Top